Why Cardiovascular Outcomes Trials Matter
For obesity medications, cardiovascular outcomes data is the difference between a niche product and a blockbuster with broad insurance coverage. Here is why:
- Medicare coverage: Before semaglutide's SELECT trial, Medicare Part D did not cover obesity medications at all. SELECT's demonstration that semaglutide reduces MACE by 20% in people with obesity and established CVD changed this — Medicare now covers Wegovy for the CV risk reduction indication. A positive TRIUMPH-3 result could unlock the same coverage for retatrutide.
- Private insurer decisions: Most large commercial insurers follow FDA label language closely. A CV label expands who qualifies for coverage beyond BMI thresholds alone.
- Prescriber confidence: Cardiologists are increasingly involved in obesity pharmacotherapy prescribing. CV outcomes data creates a persuasive case for use in the highest-risk patients.
- Competitive positioning: If retatrutide earns a CV label, it directly competes with Wegovy on the indication that drove semaglutide's most significant commercial expansion.
TRIUMPH-3 vs Semaglutide's SELECT Trial: Key Comparison
| Feature | TRIUMPH-3 (Retatrutide) | SELECT (Semaglutide / Wegovy) |
|---|---|---|
| Drug | Retatrutide (triple agonist) | Semaglutide 2.4 mg (GLP-1 single agonist) |
| NCT ID | TRIUMPH-3: NCT05882045 TRIUMPH-Outcomes: NCT06383390 | NCT03574597 |
| Population | Obesity/overweight + established CVD | Overweight/obesity + established CVD (no T2D) |
| Primary endpoint | 3-point MACE (CV death, MI, stroke) | 3-point MACE |
| SELECT result | Pending (trial active) | 20% reduction in MACE (HR 0.80, p<0.0001) |
| Enrollment | TRIUMPH-3: 1,800; TRIUMPH-Outcomes: ~10,000 | 17,604 |
| Duration | TRIUMPH-Outcomes primary completion Feb 2029; TRIUMPH-3 ~113 wks | ~34 months median follow-up |
| Impact on label | Would enable CV risk reduction indication if positive | Enabled "reduce CV risk" label; unlocked Medicare coverage |
The Glucagon Receptor Wild Card
One analytically interesting question about TRIUMPH-3 is the role of retatrutide's glucagon receptor agonism in cardiovascular outcomes. Unlike semaglutide or tirzepatide, retatrutide activates the glucagon receptor — which influences:
- Heart rate: Glucagon receptor activation increases heart rate (positive chronotropy). This could theoretically be detrimental in some cardiovascular patients. However, the magnitude in retatrutide Phase 2 trials was modest and similar to other GLP-1 agents (~4–8 bpm increase).
- Blood pressure: TRIUMPH-4 showed retatrutide reduced blood pressure — a positive cardiovascular marker.
- Hepatic fat: Glucagon receptor agonism potently reduces liver fat (hepatic steatosis), which is linked to cardiovascular risk. This could be an incremental CV benefit vs GLP-1-only agonists.
- Lipids: Phase 2 data showed improvements in lipid profiles — reduced triglycerides and improved HDL, consistent with CV benefit.
The net cardiovascular effect of triple agonism is genuinely uncertain until TRIUMPH-3 reports. The trial will be definitive — this is why it is the most consequential long-term study in the TRIUMPH program.
What Would a Positive TRIUMPH-3 Unlock?
If TRIUMPH-3 shows a statistically significant reduction in MACE comparable to SELECT's 20% reduction, retatrutide would be positioned to:
- Earn an FDA CV risk reduction label — allowing it to be prescribed for cardiovascular risk reduction in people with obesity + CVD regardless of weight loss goals alone.
- Trigger Medicare Part D coverage — the most significant access unlock for older patients in the US who currently cannot access obesity medications under traditional Medicare rules.
- Enable coverage decisions for the highest-risk commercial insurance patients — some insurers require CV data to justify obesity drug coverage in high-cost beneficiaries.
- Differentiate retatrutide from tirzepatide — tirzepatide (Zepbound/Mounjaro) does not yet have a reported major MACE outcome trial for the obesity indication.
Timeline to Expect TRIUMPH-3 Data
CV outcomes trials are the longest and most resource-intensive clinical studies in medicine. TRIUMPH-Outcomes (NCT06383390, ~10,000 participants, primary completion Feb 2029) is the event-driven MACE outcomes study; TRIUMPH-3 (NCT05882045, 1,800 participants, ~113 weeks) provides weight-loss efficacy data in the CVD population. Analysts project NDA submission in Q1–Q2 2027 (analyst consensus, not Lilly-confirmed), pending TRIUMPH-1/2 primary readouts (April 2026). Retatrutide could potentially be approved for obesity before the TRIUMPH-Outcomes MACE data are available, with a CV risk-reduction label coming as a post-approval expansion if TRIUMPH-Outcomes is positive.
Sources
- ClinicalTrials.gov — TRIUMPH-3: NCT05882045
- ClinicalTrials.gov — TRIUMPH-Outcomes: NCT06383390
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- BioSpace — TRIUMPH-4 readout (December 2025): Lilly's retatrutide scores triple trial triumph
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972